Silverback Therapeutics, Inc., a Seattle, WA-based biotechnology company developing a pipeline of systemically delivered, locally active therapies, closed an extension of its Series A financing.
The funding, which brought the total raised in the round to $47.5m, was led by existing investor OrbiMed, with participation from new investors Celgene Corporation and Alexandria Venture Investments.
Led by Peter Thompson, M.D., co-founder, CEO and chairman, Silverback is advancing a pipeline of therapies targeting fundamental disease pathways that are systemically delivered but locally active. Enabled by the company’s proprietary ImmunoTAC platform, Silverback’s pipeline is advancing towards clinical studies in several therapeutic areas, including oncology and fibrosis.
The company has filed over 15 patent families covering the ImmunoTAC platform and related product candidates.
Initial data will be disclosed at a scientific conference in 2019.